Search Results - "Şendur, M.A.N."

1807 Effect of regular exercise on survival in women with early stage luminal a breast cancer by Yazici, O, Aksoy, S, Sendur, M.A.N, Ozdemir, N, Akinci, M.B, Zengin, N, Altundag, K

Get full text

The effect of primary surgery in patients with stage IV breast cancer with bone metastasis only (protocol bomet MF14-01); a multi-center, registry study by Soran, A., Dogan, L., Ozbas, S., Isık, A., Trablus, D., Demirci, U., Karanlık, H., Soyder, A., Dag, A., Bilici, A., Dogan, M., Koksal, H., Sendur, M.A.N., Gulcelik, M.A., Maralcan, G., Cabioglu, N., Yeniay, L., Utkan, Z., Simsek, T., Karadurmus, N., Daglar, G., Yıldız, B., Uras, C., Tukenmez, M., Yildirim, A.O., Kutun, S., Ozaslan, C., Karaman, N., Akcay, M.N., Toktas, O., Sezgin, E.

Get full text

1966 Study of the impact of Charlson comorbidity index on the efficacy of adjuvant trastuzumab in patients with HER2-positive early breast cancer by Sendur, M.A.N, Aksoy, S, Silay, K, Ozdemir, N.Y, Yazici, O, Akinci, M.B, Sener Dede, D, Zengin, N, Altundag, K

Get full text

3223 The comparison of early stage primary nodal and extranodal diffuse large cell lymphomas: Clinical features, treatment and survival outcomes by Yildirim, N, Hocazade, C, Bozkaya, Y, Yazic, O, Sendur, M.A.N, Yazilitas, D, Serife, T, Arslan, S, Zengin, N

Get full text

2350 The efficacy and predictive factors of response of second line triplet (modified-EOX; epirubicin-oxaliplatin-capacitabine) regimen in metastatic gastric cancer by Sendur, M.A.N, Ozdemir, N, Aksoy, S, Yazici, O, Yazilitas, D, Akinci, M.B, Dede, D.S, Yalcin, B, Zengin, N

Get full text

3238 The effect of “international prognostic index (IPI)” in the determination of prognosis of early stage diffuse large b cell non-hodgkin lymphoma: Is it enough? by Yildirim, N, Yazici, O, Hocazade, C, Bozkaya, Y, Sendur, M.A.N, Akinci, B, Silay, K, Yazilitas, D, Topbaş, S, Zengin, N

Get full text

3354 Prognostic factors for survival in patients with metastatic melanoma treated with ipilimumab: Turkish Oncology Group (TOG) Study by Urun, Y, Abal, H, Turna, H, Esin, E, Sedef, A.M, Alkan, A, Oksüzoğlu, B, Ozdemir, N.Y, Sendur, M.A.N, Sezer, A, Kiliçkap, S, Akbulut, H, Celik, I

Get full text

2395 The importance of thiol/disulphide homeostasis in patients with advanced gastric cancer (AGC) receiving modified docetaxel and cisplatin plus fiuorouracil (mDCF) regimen by Yazici, O, Ozdemir, N, Erel, O, Demirci, N.S, Aksoy, S, Sendur, M.A.N, Dogan, M, Yazilitas, D, Erdem, G.U, Neselioglu, S, Hocazade, C, Bozkaya, Y, Bal, O, Zengin, N

Get full text

781P Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab by Tural, D., Ölmez, Ö.F., Sümbül, A.T., Özhan, N., Akar, E., Çakar, B., Köstek, O., Ekenel, M., Erman, M., Çoşkun, H.Ş., Selçukbiricik, F., Keskin, O., Paksoy, F., Oruç, K., S. Bayram, Yılmaz, U., Bilgetekin, I., Yıldız, B., Şendur, M.A.N., Artac, M.

Get full text

Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy by Kos, F T, Sendur, M A N, Aksoy, S, Sezer, S, Civelek, B, Yazici, O, Yaman, S, Eren, T, Zengin, N

“…There are some data regarding the role of cystatin C, a cysteine proteinase inhibitor, in determining the glomerular filtration rate (GFR) more accurately. We…”
Get more information

Stevens–Johnson Syndrome after Treatment with Capecitabine by Sendur, M.A.N, Kilickap, S

Get full text

1720P Experience in the provision of oncology services immediately after a major disaster by Aktas, B.Y., Karacin, C., Sendur, M.A.N., Dincer, M., Karadurmus, N.

Get full text

2373P Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361 by Mamtani, R., Matsubara, N., Montesa Pino, A., Anido Herranz, U., Sendur, M.A.N., Gravis, G., Huillard, O., Lee, H.J., Gafanov, R., Joly Lobbedez, F., Bedke, J., Sella, A., Chang, Y.H., Imai, K., Homet Moreno, B., Xu, J., Alva, A., Powles, T.B.

Get full text

663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC by Rojas, C., Lugowska, I., Juergens, R., Sacher, A., Weindler, S., Sendur, M.A.N., Dziadziuszko, R., Pal, A., Castanon Alvarez, E., Ahern, E.S., Lakhani, N., Chen, L-C., Jemielita, T., Choi, Y.S., Stathis, A.

Get full text

1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study by Gratzke, C.J., Ozguroglu, M., Peer, A., Sendur, M.A.N., Retz, M., Goh, J.C.H., Loidl, W.C., Jayram, G., Byun, S-S., Kwak, C., Kwiatkowski, M., Manneh Kopp, R., Vazquez Limon, J.C., Escobar Penagos, J.F., De Giorgi, U.F.F., Trindade, K.M.D., Niu, C., Liu, Y., Poehlein, C.H., Piulats Rodriguez, J.M.

Get full text

Tyrosine kinase inhibitors (TKI): Awareness of drug-drug interaction by Ozdemir, N., Toptas, S., Sendur, M.A.N., Yazici, O., Öksüzoğlu, B., Silay, K., Zengin, N.

Get full text

124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey by Sendur, M.A.N., Cakar, B., Hızal, M., Eraslan, E., Aksoy, S., Paydas, S., Demir, N., Sen, F., Bulut, G., Oruc, K., Oyan Uluc, B., Ozdemir, N., Sakin, A., Erdem, D., Ozkan, M., Disel, U., Ekinci, F., Okten, I.N., Ozer, L., Gokmen, E.

Get full text

PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC by Wu, Y.-L., Wang, L., Sendur, M.A.N., Kim, Y.-C., Zhu, Z., Cheng, Y., Li, P., Qin, Y., Macpherson, E., Dennis, P.A., Lu, S.

Get full text

1405P Efficacy and safety of perioperative FLOT (5-FU, LV, oxaliplatin, docetaxel) chemotherapy in gastric and gastroesophageal junction adenocarcinoma: Real-life data from Turkish oncology group by Erol, C., Basoglu, T., Sakin, A., Ozden, E., Cubuk, D., Yumuk, P.F., Dogan, M., Oksuzoglu, B., Yildirim, H.C., Oner, I., Karakurt Eryilmaz, M., Dulgar, O., Turkmen Bekmez, E., Dogan, N., Ozen, M., Gurler, F., Paksoy, N., Aksoy, A., Hizal, M., Sendur, M.A.N.

Get full text

The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM) by Sener Dede, D., Tatli Dogan, H., Asan, F.B., Gumuskaya Ocal, B., Ayik, S., Sendur, M.A.N., Ulas, A., Bilgin, B., Hizal, M., Akinci, M.B., Silay, K., Yalçın, B.

Get full text